This Neurological Disorder Diagnostics market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The neurological disorder diagnostics market size has grown strongly in recent years. It will grow from $10.98 billion in 2023 to $11.75 billion in 2024 at a compound annual growth rate (CAGR) of 7%. The growth during the historic period can be attributed to the rising prevalence of neurological disorders, an aging population, increased emphasis on early diagnosis and disease management, heightened awareness of neurological conditions, and a stronger focus on early diagnosis.
The neurological disorder diagnostics market size is expected to see strong growth in the next few years. It will grow to $15.51 billion in 2028 at a compound annual growth rate (CAGR) of 7.2%. The growth during the forecast period can be attributed to increasing awareness and education, rising healthcare expenditure, improved access to healthcare services, expansion of diagnostic centers, and a growing adoption of personalized medicine. Key trends expected include advancements in neuroimaging techniques, the adoption of wearable devices and remote monitoring technologies, progress in biomarker discovery and genetic testing, integration of artificial intelligence and machine learning, and the development of point-of-care diagnostic devices.
The growing prevalence of Alzheimer's disease is expected to drive the expansion of the neurological disorder diagnostics market in the coming years. Alzheimer's disease is a progressive neurodegenerative condition marked by a gradual deterioration in cognitive abilities, including memory, reasoning, and problem-solving. The disease involves a combination of genetic factors, such as certain gene mutations and variations, the buildup of amyloid plaques and tau tangles in the brain, chronic inflammation, vascular problems, and lifestyle influences. Neurological disorder diagnostics aid in managing Alzheimer's disease by facilitating early and accurate detection through advanced imaging techniques, biomarker analysis, and cognitive assessments. For example, in September 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that in 2023, around 411,100 people in Australia were living with dementia, including approximately 257,500 women and 153,700 men. Therefore, the rising prevalence of Alzheimer's disease is contributing to the growth of the neurological disorder diagnostics market.
Leading companies in the neurological disorder diagnostics market are concentrating on developing innovative solutions, such as neurological disease quantification software, to address the needs of the one billion people globally affected by neurological diseases. Neurological disease quantification software is a tool designed to assess and track brain function and the progression of diseases in neurological conditions. For example, in January 2024, Quibim, a biotechnology company based in Spain, introduced QP-Brain, an AI-driven software for early-stage neurological disease quantification. QP-Brain is an advanced neuroimaging analysis tool developed by Quibim to measure changes in brain tissue due to neurological diseases. Its standout features include AI-powered automated segmentation and comprehensive volumetric analysis, providing accurate insights into brain structural changes for both clinical and research purposes.
In February 2023, Lantheus, a US-based pharmaceutical manufacturer, acquired Cerveau Technologies for an undisclosed amount. This acquisition enhances Lantheus' diagnostic capabilities for Alzheimer's disease with Cerveau's tau-targeting PET imaging agent, MK-6240, improving the ability to diagnose, stage, and monitor the disease while supporting the development of new treatments. Cerveau Technologies, based in the US, specializes in diagnostic technologies for neurological disorders, particularly neurodegenerative diseases such as Alzheimer's.
Major companies operating in the neurological disorder diagnostics market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Amgen Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Otsuka Pharmaceutical Co. Ltd., Boston Scientific Corporation, Neurocrine Biosciences Inc., Neusoft Medical Systems Co.Ltd., Nihon Kohden Corporation, Natus Medical Incorporated, Esaote S.p.A, Canon Medical Systems Corporation, NeuroPace Inc., Lifelines Neuro Company LLC, York Instruments Ltd., Advanced Brain Monitoring Inc., Neurometrix Inc., Croton Healthcare Private Limited, NeuroLogica Corporation.
North America was the largest region in the neurological disorder diagnostics market in 2023. The regions covered in the neurological disorder diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the neurological disorder diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Neurological disorder diagnostics involve methods and technologies used to identify, assess, and monitor diseases affecting the nervous system, including the brain, spinal cord, and nerves. This field utilizes advanced imaging techniques, biomarker analysis, genetic testing, and cognitive assessments to detect abnormalities, determine the presence and progression of diseases, and guide treatment strategies for various neurological conditions.
The main components in the neurological disorder diagnostics market include instruments, reagents, kits, software, and services. Instruments refer to the physical devices used for diagnosing neurological disorders. Technologies in this field include immunoassays and polymerase chain reaction (PCR) techniques. The diseases covered range from Alzheimer’s disease and dementia to Parkinson’s disease, epilepsy, traumatic brain injury, and more. End users of these diagnostics include hospitals and clinics, diagnostic centers, and academic and research institutes.
The neurological disorder diagnostics market research report is one of a series of new reports that provides neurological disorder diagnostics market statistics, including the neurological disorder diagnostics industry global market size, regional shares, competitors with neurological disorder diagnostics market share, detailed neurological disorder diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the neurological disorder diagnostics industry. These neurological disorder diagnostics market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The neurological disorder diagnostics market consists of revenues earned by entities by providing services such as neuroimaging, electrophysiological testing, genetic analysis, cerebrospinal fluid examination, neuropsychological assessments, and laboratory tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurological disorder diagnostics market also includes sales of imaging devices, biomarker tests, and cognitive assessment tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The neurological disorder diagnostics market size has grown strongly in recent years. It will grow from $10.98 billion in 2023 to $11.75 billion in 2024 at a compound annual growth rate (CAGR) of 7%. The growth during the historic period can be attributed to the rising prevalence of neurological disorders, an aging population, increased emphasis on early diagnosis and disease management, heightened awareness of neurological conditions, and a stronger focus on early diagnosis.
The neurological disorder diagnostics market size is expected to see strong growth in the next few years. It will grow to $15.51 billion in 2028 at a compound annual growth rate (CAGR) of 7.2%. The growth during the forecast period can be attributed to increasing awareness and education, rising healthcare expenditure, improved access to healthcare services, expansion of diagnostic centers, and a growing adoption of personalized medicine. Key trends expected include advancements in neuroimaging techniques, the adoption of wearable devices and remote monitoring technologies, progress in biomarker discovery and genetic testing, integration of artificial intelligence and machine learning, and the development of point-of-care diagnostic devices.
The growing prevalence of Alzheimer's disease is expected to drive the expansion of the neurological disorder diagnostics market in the coming years. Alzheimer's disease is a progressive neurodegenerative condition marked by a gradual deterioration in cognitive abilities, including memory, reasoning, and problem-solving. The disease involves a combination of genetic factors, such as certain gene mutations and variations, the buildup of amyloid plaques and tau tangles in the brain, chronic inflammation, vascular problems, and lifestyle influences. Neurological disorder diagnostics aid in managing Alzheimer's disease by facilitating early and accurate detection through advanced imaging techniques, biomarker analysis, and cognitive assessments. For example, in September 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that in 2023, around 411,100 people in Australia were living with dementia, including approximately 257,500 women and 153,700 men. Therefore, the rising prevalence of Alzheimer's disease is contributing to the growth of the neurological disorder diagnostics market.
Leading companies in the neurological disorder diagnostics market are concentrating on developing innovative solutions, such as neurological disease quantification software, to address the needs of the one billion people globally affected by neurological diseases. Neurological disease quantification software is a tool designed to assess and track brain function and the progression of diseases in neurological conditions. For example, in January 2024, Quibim, a biotechnology company based in Spain, introduced QP-Brain, an AI-driven software for early-stage neurological disease quantification. QP-Brain is an advanced neuroimaging analysis tool developed by Quibim to measure changes in brain tissue due to neurological diseases. Its standout features include AI-powered automated segmentation and comprehensive volumetric analysis, providing accurate insights into brain structural changes for both clinical and research purposes.
In February 2023, Lantheus, a US-based pharmaceutical manufacturer, acquired Cerveau Technologies for an undisclosed amount. This acquisition enhances Lantheus' diagnostic capabilities for Alzheimer's disease with Cerveau's tau-targeting PET imaging agent, MK-6240, improving the ability to diagnose, stage, and monitor the disease while supporting the development of new treatments. Cerveau Technologies, based in the US, specializes in diagnostic technologies for neurological disorders, particularly neurodegenerative diseases such as Alzheimer's.
Major companies operating in the neurological disorder diagnostics market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Amgen Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Otsuka Pharmaceutical Co. Ltd., Boston Scientific Corporation, Neurocrine Biosciences Inc., Neusoft Medical Systems Co.Ltd., Nihon Kohden Corporation, Natus Medical Incorporated, Esaote S.p.A, Canon Medical Systems Corporation, NeuroPace Inc., Lifelines Neuro Company LLC, York Instruments Ltd., Advanced Brain Monitoring Inc., Neurometrix Inc., Croton Healthcare Private Limited, NeuroLogica Corporation.
North America was the largest region in the neurological disorder diagnostics market in 2023. The regions covered in the neurological disorder diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the neurological disorder diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Neurological disorder diagnostics involve methods and technologies used to identify, assess, and monitor diseases affecting the nervous system, including the brain, spinal cord, and nerves. This field utilizes advanced imaging techniques, biomarker analysis, genetic testing, and cognitive assessments to detect abnormalities, determine the presence and progression of diseases, and guide treatment strategies for various neurological conditions.
The main components in the neurological disorder diagnostics market include instruments, reagents, kits, software, and services. Instruments refer to the physical devices used for diagnosing neurological disorders. Technologies in this field include immunoassays and polymerase chain reaction (PCR) techniques. The diseases covered range from Alzheimer’s disease and dementia to Parkinson’s disease, epilepsy, traumatic brain injury, and more. End users of these diagnostics include hospitals and clinics, diagnostic centers, and academic and research institutes.
The neurological disorder diagnostics market research report is one of a series of new reports that provides neurological disorder diagnostics market statistics, including the neurological disorder diagnostics industry global market size, regional shares, competitors with neurological disorder diagnostics market share, detailed neurological disorder diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the neurological disorder diagnostics industry. These neurological disorder diagnostics market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The neurological disorder diagnostics market consists of revenues earned by entities by providing services such as neuroimaging, electrophysiological testing, genetic analysis, cerebrospinal fluid examination, neuropsychological assessments, and laboratory tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurological disorder diagnostics market also includes sales of imaging devices, biomarker tests, and cognitive assessment tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Neurological Disorder Diagnostics Market Characteristics3. Neurological Disorder Diagnostics Market Trends and Strategies32. Global Neurological Disorder Diagnostics Market Competitive Benchmarking33. Global Neurological Disorder Diagnostics Market Competitive Dashboard34. Key Mergers and Acquisitions in the Neurological Disorder Diagnostics Market
4. Neurological Disorder Diagnostics Market - Macro Economic Scenario
5. Global Neurological Disorder Diagnostics Market Size and Growth
6. Neurological Disorder Diagnostics Market Segmentation
7. Neurological Disorder Diagnostics Market Regional and Country Analysis
8. Asia-Pacific Neurological Disorder Diagnostics Market
9. China Neurological Disorder Diagnostics Market
10. India Neurological Disorder Diagnostics Market
11. Japan Neurological Disorder Diagnostics Market
12. Australia Neurological Disorder Diagnostics Market
13. Indonesia Neurological Disorder Diagnostics Market
14. South Korea Neurological Disorder Diagnostics Market
15. Western Europe Neurological Disorder Diagnostics Market
16. UK Neurological Disorder Diagnostics Market
17. Germany Neurological Disorder Diagnostics Market
18. France Neurological Disorder Diagnostics Market
19. Italy Neurological Disorder Diagnostics Market
20. Spain Neurological Disorder Diagnostics Market
21. Eastern Europe Neurological Disorder Diagnostics Market
22. Russia Neurological Disorder Diagnostics Market
23. North America Neurological Disorder Diagnostics Market
24. USA Neurological Disorder Diagnostics Market
25. Canada Neurological Disorder Diagnostics Market
26. South America Neurological Disorder Diagnostics Market
27. Brazil Neurological Disorder Diagnostics Market
28. Middle East Neurological Disorder Diagnostics Market
29. Africa Neurological Disorder Diagnostics Market
30. Neurological Disorder Diagnostics Market Competitive Landscape and Company Profiles
31. Neurological Disorder Diagnostics Market Other Major and Innovative Companies
35. Neurological Disorder Diagnostics Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Neurological Disorder Diagnostics Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on neurological disorder diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for neurological disorder diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurological disorder diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Component: Instruments; Reagents; Kits; Software; Services2) By Technology: Immunoassay; Polymerase Chain Reaction (PCR) Techniques
3) By Disease Type: Alzheimer's Disease; Dementia; Parkinson's Disease; Epilepsy; Traumatic Brain Injury; Other Disease Types
4) By End User: Hospitals And Clinics; Diagnostic Centers; Academic And Research Institutes
Key Companies Mentioned: Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Abbott Laboratories; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies profiled in this Neurological Disorder Diagnostics market report include:- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Novartis AG
- Medtronic plc
- Amgen Inc.
- Siemens Healthineers AG
- Koninklijke Philips N.V.
- GE HealthCare Technologies Inc.
- Otsuka Pharmaceutical Co. Ltd.
- Boston Scientific Corporation
- Neurocrine Biosciences Inc.
- Neusoft Medical Systems Co.Ltd.
- Nihon Kohden Corporation
- Natus Medical Incorporated
- Esaote S.p.A
- Canon Medical Systems Corporation
- NeuroPace Inc.
- Lifelines Neuro Company LLC
- York Instruments Ltd.
- Advanced Brain Monitoring Inc.
- Neurometrix Inc.
- Croton Healthcare Private Limited
- NeuroLogica Corporation
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | December 2024 |
Forecast Period | 2024 - 2028 |
Estimated Market Value ( USD | $ 11.75 Billion |
Forecasted Market Value ( USD | $ 15.51 Billion |
Compound Annual Growth Rate | 7.2% |
Regions Covered | Global |
No. of Companies Mentioned | 26 |